Physician profile
Christie Morrison
NPI 1760875165
$225,147.62
in general payments reported to CMS, 2019-2025
26 companies · $115K in 2025
The $115K reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $163 · 2022: $1,807 · 2023: $14K · 2024: $95K · 2025: $115K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $137K · Travel and Lodging: $67K · Food and Beverage: $13K · Consulting Fee: $6,211 · Education: $28.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $136,912.50 |
| Travel and Lodging | $67,148.51 |
| Food and Beverage | $12,877.20 |
| Consulting Fee | $6,210.50 |
| Education | $28.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $199,143.89 | 2021-2025 | |
| Pfizer INC. | $11,961.12 | 2022-2025 | |
| Lilly USA, LLC | $6,296.65 | 2023-2025 | Omvoh |
| Janssen Biotech, INC. | $1,788.68 | 2022-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,738.30 | 2022-2025 | Entyvio, Eohilia |
| E.R. Squibb & Sons, L.L.C. | $1,258.72 | 2021-2024 | Zeposia |
| Enterra Medical, INC. | $526.72 | 2023 | |
| Janssen Scientific Affairs, LLC | $463.64 | 2024-2025 | Stelara, Tremfya |
| Celgene Corporation | $450.00 | 2022-2024 | Zeposia |
| Genzyme Corporation | $299.19 | 2022-2024 | |
| Redhill Biopharma INC. | $276.93 | 2022-2024 | Talicia, Aemcolo, Movantik |
| Regeneron Healthcare Solutions, INC. | $153.14 | 2022-2025 | Dupixent |
| Boston Scientific Corporation | $142.73 | 2024 | Compliance Endokit |
| Madrigal Pharmaceuticals | $124.92 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.11 | 2022-2024 | Trulance, Xifaxan |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $70.68 | 2022-2023 | Injectafer |
| Exact Sciences Corporation | $66.90 | 2023-2025 | The Cologuard Plus Collection Kit |
| Celltrion USA INC. | $62.47 | 2023-2025 | Vegzelma, Yuflyma |
| Ipsen Biopharmaceuticals, INC | $40.39 | 2024-2025 | Iqirvo |
| Ferring Pharmaceuticals INC. | $40.25 | 2022-2023 | Rebyota |
| Ardelyx, INC. | $35.38 | 2023 | Ibsrela |
| Braintree Laboratories, INC. | $26.61 | 2022 | |
| Ironwood Pharmaceuticals, INC | $24.97 | 2023 | Linzess |
| Astrazeneca Pharmaceuticals Lp | $18.60 | 2022 | |
| Aimmune Therapeutics, INC. | $18.33 | 2024 | |
| Merck Sharp & Dohme LLC | $14.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christie Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.